Oberland Capital, a NYC-based healthcare focused investment firm, closed its second royalty and credit opportunities fund, at $800m.
Investors in Oberland Capital Healthcare II LP include public and corporate pension plans, financial institutions, foundations and endowments located in the United States, Europe and the Middle East.
Fund II will target investments between $20m and $150m with a focus on commercial stage or near-commercial stage biopharmaceutical, medical device and diagnostic companies and royalty-bearing products.
Founded in 2013 and led by Managing Partners Andrew Rubinstein and Jean-Pierre Naegeli, Oberland Capital is a private investment firm with over $1.2 billion in capital commitments since inception, which is focused exclusively on investing in the global healthcare industry.
The firm’s suite of financing solutions includes monetization of royalty streams, acquisition of future product revenues, creation of project-based financing structures, and investment in debt and equity securities.
The team also includes:
– William Clifford, Partner
– Michael Bloom, Principal
– Jesper Wiklund, Managing Director, Europe
– David Dubinsky, Chief Financial Officer
– Johnna Schifilliti, Director
– CN Chen, CFA, Director
FinSMEs
12/09/2018